ACPP	Activatable cell penetrating peptide
ADA	Anti drug Antibody
ADC	Antibody drug conjugate
ANG	Angiopep-2
AuNPs	Gold nanoparticles
BBB	Blood–brain barrier
CCRCC	Clear cell renal cell carcinoma
CPP	Cell-penetrating peptide
CPT	Camptothecin
CRPC	Castration resistant prostate cancer
CTP	Cell-targeting peptide
DCR	Disease Control Rate
DOTA	Tetraazacyclododecane-tetraacetic acid
DMA	2,3-dimethylmaleic anhydride
ES-SCLC	Extensive Stage Small Cell Lung Cancer
FAP	Fibroblast Activation Protein
FDA	Food and Drug Administration
GEP-NETs	Gastroenteropancreatic neuroendocrine tumors
HR	Hormone Receptor
IRIT	Intracavitary radioimmunotherapy
IV	Intravenous
mAb	Monoclonal antibody
MCRPC	Metastatic Castration-resistant Prostate Cancer
MHNPC	Metastatic hormone-naive prostate cancer
MOA	Mechanism of action
MT1-MMP	Membrane type 1 metalloproteinase
NET	Neuroendocrine tumor
NSCLC	Non-Small Cell Lung Cancer
ODD	Oxygen-dependent degradation
OHSPC	Oligometastatic hormone-sensitive prostate cancer
PABC	Valine-citrulline-p-aminobenzyloxycarbonyl
PDC	Peptide drug conjugate
PEG	Polyethylene glycol
P.K.	Pharmacokinetics
PSMA	Prostate-specific membrane antigen
PSar	Polysarcosine
PTX	Paclitaxel
RLT	Radioligand therapy
RMT	Radiometabolic Therapy
SBRT	Stereotactic body radiotherapy
SCLC	Small cell lung cancer
siRNA	short interfering RNA
SORT1	sortilin1
STTR	Somatostatin receptor
TATE	Tyr3-octreotate
T-DM1	Trastuzumab
TNBC	Triple Negative Breast Cancer
VEGF	Vascular Endothelial Growth Factor
WDpNET	Well differentiated pancreatic neuroendocrine tumors